Belgium's Agomab Therapeutics raises $200 million in US IPO

Feb 5 (Reuters) - Agomab Therapeutics has raised $200 million in its U.S. initial public offering, the company said on Thursday, setting the stage for a Nasdaq debut by the biopharmaceutical firm.

Agomab sold 12.5 million American Depositary Shares at $16 apiece, within its marketed range of $15 to $17 per ADS. The IPO valued the company at $779.8 million.

Soaring equity markets and pent-up demand for new listings have sparked a flurry of activity in early 2026.

This will be the busiest week for sizable offerings since 2021, according to IPO-focused research and ETFs provider Renaissance Capital, as listing activity picks up pace after a historic U.S. government shutdown disrupted deal flow last year.

Agomab is focused on developing treatments for immune and inflammatory diseases, starting with chronic fibrotic conditions.

Its pipeline includes ontunisertib (AGMB‑129), an oral, gut-restricted ALK5 inhibitor for fibrostenosing Crohn's disease, a severe form of Crohn's characterized by inflammation-driven structures that often lead to surgery.

The company posted a net loss of 45.1 million euros ($53.10 million) for the nine-month period ended September 30, from a loss of 34.5 million euros in the year-ago period.

The company will list on Nasdaq under the ticker symbol "AGMB."

J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen are underwriters for the offering.

($1 = 0.8494 euros)